ArticleCancer science2024

Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.

Naomi Onda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.